Aquestive Therapeutics, Inc. (AQST) stock
Close on Nov 13, 2026Market cap $490.75MP/E –Yield –
Aquestive Therapeutics, Inc. grew revenue 12.5% to $48.84M over the twelve months to Sep 30, 2026. Free cash flow was -$40.70M. At the latest close the market valued the company at $490.75M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $490.75M
- P/E ratio
- –
- Price to sales
- 10.05
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -8.29%
Fundamentals
- Revenue
- $48.84M
- Net income
- -$79.28M
- EPS, diluted
- -$0.64
- Free cash flow
- -$40.70M
- Book value per share
- -$0.56
- Diluted shares
- 126M
Trading
- Next earnings
- Mar 3, 2027 (estimated, after the close)
- Previous close
- $3.57
- Open
- $3.64
- Day's range
- $3.59 – $3.96
- Volume
- 3,966,973
- Average volume (20 days)
- 2,528,459
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 1.45
- 52-week range
- $2.93 – $6.74
- RSI (14 days)
- 47.8
- Volatility (1 year)
- 77.0%
- Relative volume
- 1.52×
- WACC
- 12.3%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | AQST | S&P 500 | Difference | AQST per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -16.3% | -3.0% | −13.2 pts | ||
| 3 months | -8.0% | -2.8% | −5.2 pts | ||
| Year to date | -39.5% | +11.5% | −51.0 pts | ||
| 1 year | -26.2% | +13.5% | −39.7 pts | ||
| 3 years | +132.7% | +77.7% | +55.0 pts | +32.5% | +21.1% |
| 5 years | -37.8% | +72.6% | −110.4 pts | -9.1% | +11.5% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Aquestive Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Update
- Update
- Update
About Aquestive Therapeutics
Pharmaceutical Preparations
Aquestive Therapeutics is a pharmaceutical company that develops and manufactures medicines using proprietary drug delivery technologies, such as its PharmFilm oral soluble film and AdrenaVerse epinephrine prodrug platform. The company designs alternatives to invasive administrations for conditions including severe allergic reactions, central nervous system disorders, and opioid dependence. Its pipeline includes Anaphylm sublingual film for anaphylaxis and AQST-108 topical gel for alopecia areata. Aquestive also collaborates with pharmaceutical partners, serving as an exclusive manufacturer for commercialized licensed products such as Suboxone, Sympazan, and Ondif. Its customers and end users include commercial licensee partners, healthcare providers, and patients requiring alternative drug administration methods.
Company profile, executives and historyAquestive Therapeutics stock: common questions
What is Aquestive Therapeutics's stock price?
AQST closed at $3.91 on Nov 13, 2026, up 9.52% on the day. Over the past 52 weeks it traded between $2.93 and $6.74.
What is Aquestive Therapeutics's market cap?
Aquestive Therapeutics was worth $490.75M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is AQST's P/E ratio?
Aquestive Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.64), so it has no meaningful P/E ratio.
How much revenue does Aquestive Therapeutics make?
Aquestive Therapeutics reported revenue of $48.84M for the twelve months to Sep 30, 2026, up 12.5% from a year earlier.
Does Aquestive Therapeutics pay a dividend?
No. Aquestive Therapeutics has not paid a cash dividend over the last twelve months.
When does Aquestive Therapeutics report earnings next?
Aquestive Therapeutics is expected to report Q4 FY2026 results on Mar 3, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has AQST stock performed over the past year?
Including dividends, AQST returned -26.2% over the past year, against +13.5% for the S&P 500.
How many AQST shares are sold short?
29M shares were sold short at the latest FINRA report, 24.13% of the float, or 13.2 days of average trading volume.
Who are Aquestive Therapeutics's competitors?
Companies most similar to Aquestive Therapeutics by business, industry and size include TNXP, ABEO, OCUL, AYTU, FBIO.
See a number that looks wrong?